CXCL11 promotes self-renewal and tumorigenicity of α2δ1+ liver tumor-initiating cells through CXCR3/ERK1/2 signaling

Zhang, Yuan; Zhao, Wei; Li, Sheng; Lv, Mengzhu; Yang, Xiaodan; Li, Meng; Zhang, Zhiqian

doi:10.1016/j.canlet.2019.02.016

Cited by 50 publications

(34 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A high level of CXCL11 is associated with worse TNM staging in patients with pancreatic cancer (PC), enhancing the proliferation and metastasis of PC cells (Ge et al, 2020). In addition, CXCL11 participants in the maintenance of the stem cell-like properties of hepatocellular carcinoma (HCC) α2δ1 + tumor initiating cells (TICs), and promotes self-renewal and tumorigenicity in α2δ1 + liver TICs through CXCR3/ERK1/2 signaling (Zhao et al, 2013;Zhang et al, 2019). The paradox of the opposing effects of CXCL11 expression may be due to the context-specific manner by which CXCL11 regulates cellular processes through different regulatory networks.…”

Section: Discussionmentioning

confidence: 99%

CXCL11 Correlates With Antitumor Immunity and an Improved Prognosis in Colon Cancer

Cao

Jiao

Sun

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The chemokine ligand C-X-C motif chemokine ligand 11 (CXCL11) is involved in the progression of various cancers, but its biological roles in colorectal cancer (CRC) remain confused. Therefore, the prognostic value and underlying mechanism of CXCL11 in CRC were preliminarily evaluated. Three independent datasets were used for mRNA-related analysis: one dataset from the Cancer Genome Atlas (TCGA, n = 451) and two single-cell RNA sequencing (scRNA-seq) datasets from Gene Expression Omnibus (GEO): GSE146771 and GSE132465. In addition, a colon adenocarcinoma (COAD) patient cohort (the Yijishan Hospital cohort, YJSHC, n = 108) was utilized for analysis of cell infiltration by immunohistochemistry. We determined the distribution of CXCL11 in tumor tissue across all TCGA cancers and found that CXCL11 expression was significantly upregulated in both COAD and rectal adenocarcinoma (READ). However, the upregulation of CXCL11 mRNA was associated with a better prognosis in COAD, but not in READ. Within the YJSHC, the patients with a high abundance of intratumoral CXCL11+ cells had prolonged survival (p = 0.001). Furthermore, we found that the high CXCL11 expression group had a higher proportion of antitumor immune cells, and a lower proportion of protumor immune cells. Additionally, we discovered the changes of gene expression and enriched immune pathway network mediated by CXCL11. Interestingly, both cytotoxic genes (IFNG, GZMA, GZMB, GZMK, GZMM, and PRF1) and immunosuppressive molecules, including PD-L1, were positively correlated with CXCL11 expression. CXCL11, which promoted antitumor immunity to benefit survival, was identified as an independent prognostic biomarker in patients with COAD.

show abstract

Section: Discussionmentioning

confidence: 99%

CXCL11 Correlates With Antitumor Immunity and an Improved Prognosis in Colon Cancer

Cao

Jiao

Sun

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…It has also been described that the repression of CXCL11 in CRC tissues diminished the tumor cell growth and metastasis [113]. In addition, the observed increased expression of CXCL11 in HCC cells was linked with the upregulation of stem cell-related genes and the acquisition and maintenance of self-renewal and tumorigenic properties of tumor-initiating cells through an autocrine axis [114].…”

Section: The Crosstalk Of the Cxcr3 Variants And Their Chemokine Lmentioning

confidence: 99%

The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment

Reynders

Abboud

Baragli

et al. 2019

Cells

View full text Add to dashboard Cite

First thought to orchestrate exclusively leukocyte trafficking, chemokines are now acknowledged for their multiple roles in the regulation of cell proliferation, differentiation, and survival. Dysregulation of their normal functions contributes to various pathologies, including inflammatory diseases and cancer. The two chemokine receptor 3 variants CXCR3-A and CXCR3-B, together with their cognate chemokines (CXCL11, CXCL10, CXCL9, CXCL4, and CXCL4L1), are involved in the control but also in the development of many tumors. CXCR3-A drives the infiltration of leukocytes to the tumor bed to modulate tumor progression (paracrine axis). Conversely, tumor-driven changes in the expression of the CXCR3 variants and their ligands promote cancer progression (autocrine axis). This review summarizes the anti- and pro-tumoral activities of the CXCR3 variants and their associated chemokines with a focus on the understanding of their distinct biological roles in the tumor microenvironment.

show abstract

“…Furthermore, researchers have uncovered that CXCL11 could influence the development of colorectal cancer, BC, gastric cancer, and esophageal cancer. [21][22][23] After collecting colorectal cancer tissue samples, Gao et al found that CXCL11 was overexpressed in colorectal cancer tissues and that CXCL11 silence reduced tumor growth and metastasis in vivo. 16 Liu et al, on the other hand, used the digital gene expression sequencing technique to compare the gene expression profiling between the pathological complete response samples and the non-pathological complete response samples.…”

Section: Discussionmentioning

confidence: 99%

miR-1298-5p Influences the Malignancy Phenotypes of Breast Cancer Cells by Inhibiting CXCL11

Zhang¹,

Hu²

2021

CMAR

View full text Add to dashboard Cite

CXCL11 promotes self-renewal and tumorigenicity of α2δ1+ liver tumor-initiating cells through CXCR3/ERK1/2 signaling

Cited by 50 publications

References 31 publications

CXCL11 Correlates With Antitumor Immunity and an Improved Prognosis in Colon Cancer

CXCL11 Correlates With Antitumor Immunity and an Improved Prognosis in Colon Cancer

The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment

miR-1298-5p Influences the Malignancy Phenotypes of Breast Cancer Cells by Inhibiting CXCL11

Contact Info

Product

Resources

About